Cytotoxic Action of N-aryl, Furan-derived Aminophosphonates against HT29 and HCT116 Cancer Cell Lines
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: The anticancer activity of aminophosphonic derivatives has been described extensively, some recent papers included furan-derived aminophosphonates and their cytostatic action against various cancer cells.
OBJECTIVE: A series of twelve furan-derived dibenzyl and diphenyl aminophosphonates 2a-f and 3a-f was synthesized and tested in aspect of their cytotoxic action on two cell lines of colorectal cancer: HT29 and HCT116. Seven of them are new compounds, while the rest five have already been published by us, together with their cytotoxic action against squamous esophageal cancer cells.
METHODS: To estimate the cytotoxicity effect of tested compounds MTT test was used. Pro-apoptotic activity of five selected compounds was evaluated using APC Annexin V Apoptosis Detection Kit on a flow cytometer. Quantification of caspases 3/7 activity was performed using Caspase-Glo® 3/7 Assay Kit.
RESULTS: Five of these aminophosphonates showed significant cytotoxicity higher than those of cisplatin. Simultaneous evaluation of their cytotoxicity against PBLs revealed that these compounds are rather not harmful for regular human lymphocytes. Tests on apoptosis vs. their necrotic actions on cells were performed with selected compounds showing the most significant cytotoxicity against cancer cells and all tested compounds did not induce significant increase of necrosis in cells, whereas they showed moderate-to-strong proapoptotic actions even at the lowest applied concentration. Caspase 3/7 activity results confirmed proapoptotic properties of tested aminophosphonates.
CONCLUSION: From among studied compounds, dibenzyl N-phenyl substituted amino(2-furyl)methylphsophonates were found to be more potent compounds in aspect of their antiproliferative action than the corresponding diphenyl derivatives.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
---|---|
Enthalten in: |
Anti-cancer agents in medicinal chemistry - 19(2019), 4 vom: 08., Seite 453-462 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lewkowski, Jarosław [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 27.02.2020 Date Revised 27.02.2020 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1871520619666181122115649 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM290970083 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM290970083 | ||
003 | DE-627 | ||
005 | 20231225065852.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1871520619666181122115649 |2 doi | |
028 | 5 | 2 | |a pubmed24n0969.xml |
035 | |a (DE-627)NLM290970083 | ||
035 | |a (NLM)30465513 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lewkowski, Jarosław |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cytotoxic Action of N-aryl, Furan-derived Aminophosphonates against HT29 and HCT116 Cancer Cell Lines |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.02.2020 | ||
500 | |a Date Revised 27.02.2020 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a BACKGROUND: The anticancer activity of aminophosphonic derivatives has been described extensively, some recent papers included furan-derived aminophosphonates and their cytostatic action against various cancer cells | ||
520 | |a OBJECTIVE: A series of twelve furan-derived dibenzyl and diphenyl aminophosphonates 2a-f and 3a-f was synthesized and tested in aspect of their cytotoxic action on two cell lines of colorectal cancer: HT29 and HCT116. Seven of them are new compounds, while the rest five have already been published by us, together with their cytotoxic action against squamous esophageal cancer cells | ||
520 | |a METHODS: To estimate the cytotoxicity effect of tested compounds MTT test was used. Pro-apoptotic activity of five selected compounds was evaluated using APC Annexin V Apoptosis Detection Kit on a flow cytometer. Quantification of caspases 3/7 activity was performed using Caspase-Glo® 3/7 Assay Kit | ||
520 | |a RESULTS: Five of these aminophosphonates showed significant cytotoxicity higher than those of cisplatin. Simultaneous evaluation of their cytotoxicity against PBLs revealed that these compounds are rather not harmful for regular human lymphocytes. Tests on apoptosis vs. their necrotic actions on cells were performed with selected compounds showing the most significant cytotoxicity against cancer cells and all tested compounds did not induce significant increase of necrosis in cells, whereas they showed moderate-to-strong proapoptotic actions even at the lowest applied concentration. Caspase 3/7 activity results confirmed proapoptotic properties of tested aminophosphonates | ||
520 | |a CONCLUSION: From among studied compounds, dibenzyl N-phenyl substituted amino(2-furyl)methylphsophonates were found to be more potent compounds in aspect of their antiproliferative action than the corresponding diphenyl derivatives | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Furan-derived aminophosphonates | |
650 | 4 | |a antiproliferative | |
650 | 4 | |a apoptosis | |
650 | 4 | |a caspase activity | |
650 | 4 | |a colorectal cancer cells | |
650 | 4 | |a cytotoxicity. | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Furans |2 NLM | |
650 | 7 | |a Membrane Lipids |2 NLM | |
650 | 7 | |a Organophosphonates |2 NLM | |
650 | 7 | |a Phosphatidylserines |2 NLM | |
700 | 1 | |a Rzeszotarska, Edyta |e verfasserin |4 aut | |
700 | 1 | |a Matusiak, Agnieszka |e verfasserin |4 aut | |
700 | 1 | |a Morawska, Marta |e verfasserin |4 aut | |
700 | 1 | |a Gajek, Gabriela |e verfasserin |4 aut | |
700 | 1 | |a Nowak, Karolina |e verfasserin |4 aut | |
700 | 1 | |a Kontek, Renata |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d 2006 |g 19(2019), 4 vom: 08., Seite 453-462 |w (DE-627)NLM160693403 |x 1875-5992 |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2019 |g number:4 |g day:08 |g pages:453-462 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871520619666181122115649 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 19 |j 2019 |e 4 |b 08 |h 453-462 |